MGB
NRIX icon

Mass General Brigham’s Nurix Therapeutics NRIX Stock Holding History

Mass General Brigham’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,904
Closed -$476K – 9
2021
Q3 		$476K Buy
+15,904
New +$491K 0.13% 6

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Mass General Brigham's NRIX Position: Q4 2021 in Review

Mass General Brigham sold out of Nurix Therapeutics (NRIX) in Q4 2021, closing a stake of 15,904 shares — an estimated $476K sold.

Mass General Brigham first reported a position in NRIX in Q3 2021 and held it in 1 quarter. The position peaked at $476K in Q3 2021. 125 funds tracked by Wall St. Rank hold NRIX as of Q4 2021.

  • Mass General Brigham reported no remaining Nurix Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Mass General Brigham sold 15,904 Nurix Therapeutics shares in Q4 2021, an estimated $476K.
  • Mass General Brigham first reported a position in Nurix Therapeutics in Q3 2021 and held it in 1 quarter.
  • Mass General Brigham's Nurix Therapeutics position peaked at $476K in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2021.

Based on Mass General Brigham's 13F filing for Q4 2021, filed 19 Jan 2022.